Showing results (111-120 of 121) with videos related to
Sort By:
Pageof 13
Journal of the National Cancer Institute|October 8, 1999
Growth regulation of prostatic stromal cells by prostate-specific antigenD M Sutkowski, R L Goode, J Baniel, et al.The Journal of Urology|January 1, 1986
Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the ratB L Neubauer, K G Bemis, K L Best, et al.The Prostate|January 1, 1986
Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the ratB L Neubauer, K G Bemis, K L Best, et al.Thrombosis Research|April 1, 1988
Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the ratG F Smith, B L Neubauer, J L Sundboom, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1981
Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agentD A Goodwin, C F Meares, L H DeRiemer, et al.Toxicology and Applied Pharmacology|February 1, 1990
Endocrine effects of a new histamine H2-receptor antagonist, nizatidine (LY139037), in the male ratB L Neubauer, R L Goode, K L Best, et al.The Prostate|January 1, 1993
LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male ratsB L Neubauer, K L Best, T R Blohm, et al.The Prostate|October 1, 1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma modelB L Neubauer, K L Best, D F Counts, et al.The Prostate|January 1, 1993
Endocrine and antiprostatic effects of raloxifene (LY156758) in the male ratB L Neubauer, K L Best, J A Clemens, et al.The Journal of Steroid Biochemistry and Molecular Biology|May 1, 1996
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cellsM Kaefer, J E Audia, N Bruchovsky, et al.Pageof 13